Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Smith & Nephew SNATS Inc(SNN)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for SNN
10/23/2026: SNN (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Smith & Nephew is a well-established medical technology company providing orthopedic implants, sports medicine tools, and wound care solutions. Its core strength lies in its specialized portfolio and the growing adoption of its CORI surgical robotics system, which helps drive long-term equipment and service revenue. While it benefits from steady demand for elective procedures, the company faces significant competition from larger, diversified medical device players and persistent pricing pressures. The investment story centers on operational improvement and digital surgical innovation. Smith & Nephew is well-suited for value or income-oriented investors, though interested parties should monitor surgical volumes, margin expansion progress, and competitive market share shifts.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | The company offers moderate growth potential tied to digital surgery adoption rather than hyper-growth. |
| Momentum investor | Weak fit | Momentum is typically contingent on clear, sustained breakouts, which are less frequent in this steady-state sector. |
| Value investor | Strong fit | The stock often trades at valuations that may interest investors seeking established market players at reasonable multiples. |
| Dividend investor | Strong fit while signal remains positive | The company provides a reliable dividend stream suitable for income-focused portfolios. |
| Low-risk investor | Strong fit | Healthcare is generally defensive, offering lower volatility compared to cyclical growth sectors. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | Medium | The stock can be sensitive to elective surgical volume trends and macroeconomic news. |
| Valuation risk | Low | Current trading levels generally reflect historical performance rather than speculative expectations. |
| Competition risk (Medical Devices) | High | Competitors like Stryker and JNJ hold significant scale and pricing power. |
| Business quality | Strong | The company operates in a necessary, high-barrier healthcare segment with entrenched clinical relationships. |
| Dividend income | Medium | Yield is consistent, though growth is rarely aggressive. |
| Execution risk | Medium / high | Effective delivery on productivity plans is crucial for margin expansion. |
Price Behavior
Downtrend
The stock has experienced a sustained decline in price over recent periods.
Smooth
The stock has moved along a generally orderly path with only modest fluctuations.
Analysis of Past Performance
Type Stock | Historic Profit 22.42% | Avg. Invested days 42 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Advisory Rating  | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 10/23/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 12.92B USD | Price to earnings Ratio 21.01 | 1Y Target Price 32.32 |
Price to earnings Ratio 21.01 | 1Y Target Price 32.32 | ||
Volume (30-day avg) 1.2M shares | Beta 0.67 | 52 Weeks Range 26.07 - 36.11 | Updated Date 10/23/2026 |
52 Weeks Range 26.07 - 36.11 | Updated Date 10/23/2026 | ||
Dividends yield (FY) 2.57% | Basic EPS (TTM) 1.47 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Orthopedics | Hip and knee implants and robotic surgical systems. | The company profits when hospitals buy their specialized hardware for joint surgeries. |
| Sports Medicine & ENT | Repair kits and surgical instruments for soft tissue. | Revenue comes from frequent, high-volume sales of tools for sports-related injury repairs. |
| Advanced Wound Management | Specialized dressings and healing devices. | This is a recurring revenue stream as hospitals consume these products daily for patient care. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Valuation
Trailing PE 21.01 | Forward PE 11.16 | Enterprise Value 14.56B | Price to Sales(TTM) 2.05 |
Enterprise Value 14.56B | Price to Sales(TTM) 2.05 | ||
Enterprise Value to Revenue 2.31 | Enterprise Value to EBITDA 9.26 | Shares Outstanding 418.52M | Shares Floating 2.11B |
Shares Outstanding 418.52M | Shares Floating 2.11B | ||
Percent Insiders 0.01 | Percent Institutions 11.45 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.